Results 151 to 160 of about 309,789 (330)

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang   +8 more
wiley   +1 more source

Defective neutrophil-derived exosomes facilitate macrophage activation through miR-122-5p in Behçet’s disease

open access: yesNature Communications
Behçet’s disease (BD) is a life-threatening systemic vasculitis characterized by polymorphonuclear neutrophils (PMN) and macrophage activation. However, the interaction of PMN and macrophages remains elusive.
Xin Yu   +16 more
doaj   +1 more source

CRISPR/Cas9 in allergic and immunologic diseases. [PDF]

open access: yesExpert Rev Clin Immunol, 2017
Goodman MA   +3 more
europepmc   +1 more source

Hospital Readmission After Traumatic Brain Injury Hospitalization in Community‐Dwelling Older Adults

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the risk of hospital readmission after an index hospitalization for TBI in older adults. Methods Using data from the Atherosclerosis Risk in Communities (ARIC) study, we used propensity score matching of individuals with an index TBI‐related hospitalization to individuals with (1) non‐TBI hospitalizations (primary analysis)
Rachel Thomas   +7 more
wiley   +1 more source

Regulatory dendritic cells for immunotherapy in immunologic diseases. [PDF]

open access: yesFront Immunol, 2014
Gordon JR   +4 more
europepmc   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Linkage between genotype and immunological phenotype in Crohn's disease.

open access: green, 2015
Gwenny M. Fuhler   +3 more
openalex   +2 more sources

Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood [PDF]

open access: gold, 2020
Antonio Mastrangelo   +3 more
openalex   +1 more source

Immunological Diseases [PDF]

open access: yesAnnals of the Rheumatic Diseases, 1980
openaire   +1 more source

Home - About - Disclaimer - Privacy